MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
84.64
-0.47 (-0.55%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close85.11
Open84.73
Bid0.00 x 2200
Ask87.00 x 2200
Day's Range84.00 - 84.91
52 Week Range76.41 - 89.72
Volume4,705,519
Avg. Volume5,138,667
Market Cap114.719B
Beta0.73
PE Ratio (TTM)41.41
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.84 (2.14%)
Ex-Dividend Date2018-03-22
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will Medtronic (MDT) Q4 Earnings Show Growth in All Lines?
    Zacks2 days ago

    Will Medtronic (MDT) Q4 Earnings Show Growth in All Lines?

    We are upbeat about solid quarterly growth on the prosperous execution of three growth strategies, namely therapy innovation, globalization and a rise in Medtronic's (MDT) economic value.

  • Medtronic Initiates Study on DES for Expanded Use in the US
    Zacks3 days ago

    Medtronic Initiates Study on DES for Expanded Use in the US

    Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.

  • Mazor Robotics Starts Its "Transition" Year Strong
    Motley Fool5 days ago

    Mazor Robotics Starts Its "Transition" Year Strong

    Business is booming for the robotic surgery upstart.

  • Mazor Robotics (MZOR) Q1 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Mazor Robotics (MZOR) Q1 2018 Earnings Conference Call Transcript

    MZOR earnings call for the period ending March 31, 2018.

  • Estimating The Intrinsic Value Of Medtronic plc (NYSE:MDT)
    Simply Wall St.6 days ago

    Estimating The Intrinsic Value Of Medtronic plc (NYSE:MDT)

    I am going to run you through how I calculated the intrinsic value of Medtronic plc (NYSE:MDT) using the discounted cash flow (DCF) method. If you want to learn moreRead More...

  • 3 New Healthcare Stocks to Buy Right Now
    InvestorPlace6 days ago

    3 New Healthcare Stocks to Buy Right Now

    As we continue to age and populations grow, demand for new and innovative healthcare solutions is only growing as well. Already preliminary data shows that MOR208 could be a better therapy than the so-called cell therapies when used in combination to cure cancer.

  • InvestorPlace11 days ago

    Intricon Corp Is a Small Company Rising Quickly

    Intricon Corporation (NASDAQ: IIN) is up more than 223% in the past year. After a big move like that, you would expect a small cap like this to be overvalued. It makes small wearable medical devices smaller and better.

  • TheStreet.com12 days ago

    Here's How Medtronic Can Unlock Shareholder Value, Says Analyst

    Investors on Monday, May 7, cheered the news of former JPMorgan & Co. "I think they need to buy back stock," said Evercore ISI analyst Vijay Kumar in an interview with TheStreet on Tuesday. Noting that Medtronic has cash and short-term investments totaling more than $14 billion, Kumar said repurchasing shares is a way of reassuring the market that the company finds its shares compelling at these levels.

  • A Look at Abbott Laboratories’ Valuation Multiples
    Market Realist12 days ago

    A Look at Abbott Laboratories’ Valuation Multiples

    On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.

  • Why Teva Pharmaceutical Industries, Gramercy Property Trust, and Medtronic Jumped Today
    Motley Fool13 days ago

    Why Teva Pharmaceutical Industries, Gramercy Property Trust, and Medtronic Jumped Today

    Find out which of these stocks got a buyout bid.

  • Medtronic Hires JPMorgan Analyst, and Investors Rate It a ‘Buy’
    Bloomberg13 days ago

    Medtronic Hires JPMorgan Analyst, and Investors Rate It a ‘Buy’

    For about 20 years at JPMorgan Chase & Co., Mike Weinstein covered Medtronic Plc as an analyst, raising his target price on the stock from $42 to $90. Weinstein will start immediately as a senior vice president of strategy, reporting to Chief Financial Officer Karen Parkhill, Medtronic said in a statement Monday. The company has trailed rivals, grappling with natural disasters including hurricanes and wildfires, and man-made issues such as a shortfall in production of its hottest diabetes devices.

  • Reuters14 days ago

    BRIEF-Lifetech Scientific Corp Receives Notice From Medtronic Group That Medtronic Entered Deal

    May 7 (Reuters) - Lifetech Scientific Corp: * RECEIVES NOTICE FROM MEDTRONIC GROUP THAT MEDTRONIC ENTERED DEAL WITH CHINA EVERBRIGHT LTD & ANOTHER INVESTOR * AS PER DEAL, MEDTRONIC GROUP SELLS 22.4 PERCENT ...

  • Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects
    Market Realist16 days ago

    Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

    Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.

  • ABT’s Recent Stock Slump: What’s behind the Decline?
    Market Realist17 days ago

    ABT’s Recent Stock Slump: What’s behind the Decline?

    On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.

  • Analysts’ Recent Recommendations and Target Price for ABT Stock
    Market Realist17 days ago

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.

  • Is Medtronic a Buy? 1 Analyst Thinks So
    Motley Fool23 days ago

    Is Medtronic a Buy? 1 Analyst Thinks So

    But that analyst is wrong.

  • Stocks Rally As Investors Like Facebook Results, AMD Powers Chips
    Investor's Business Daily24 days ago

    Stocks Rally As Investors Like Facebook Results, AMD Powers Chips

    Key stock index funds rose Thursday as the FANG stocks and other big-cap techs powered big gains in the tech-heavy PowerShares QQQ Trust.

  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realist25 days ago

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • Will BSX’s 1Q18 Results Support Its Upward Trend?
    Market Realist26 days ago

    Will BSX’s 1Q18 Results Support Its Upward Trend?

    Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist27 days ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings
    Market Realist27 days ago

    Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings

    The company has been growing aggressively through strategic acquisitions. This month, the company announced the acquisition of Nvision Medical Corporation in the area of women’s health and Securus Medical in the area of electrophysiology. The company is slated to announce its 1Q18 earnings results on April 25. In this article, let’s discuss the company’s Wall Street recommendations and target prices for the next 12 months.

  • Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
    Investor's Business Dailylast month

    Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves

    Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.

  • Benzingalast month

    Medtech Supplier IntriCon Rallies After Bullish Stifel Initiation

    IntriCon Corporation (NASDAQ: IIN ), a medical technology company and major supplier to  Medtronic PLC (NYSE: MDT )'s diabetes division, is "one of the more interesting and undiscovered small-cap ...